Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224258 · ClinicalTrials.gov registry record · NA
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT05224258: Completed NA study, sponsored by Medtronic MiniMed.
NCT05224258 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05224258, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.
Interventions
- DEVICE MiniMed 780G System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2024-06-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224258
The ClinicalTrials.gov registry entry for NCT05224258 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic MiniMed, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MiniMed 780G System is the first listed.
NCT05224258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05224258 about?
NCT05224258 is a clinical study titled "Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®". This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.
What is the current status of trial NCT05224258?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2022-03-17. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT05224258?
The interventions under investigation include: MiniMed 780G System (DEVICE).
Who is sponsoring clinical trial NCT05224258?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.